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Background: Familial and acquired thrombophilia are often etiologic for idiopathic hip and jaw osteonecrosis (ON),
and testosterone therapy (TT) can interact with thrombophilia, worsening ON.
Case presentation: Case 1: A 62-year-old Caucasian male (previous deep venous thrombosis), on warfarin 1 year
for atrial fibrillation (AF), had non-specific right hip-abdominal pain for 2 years. CT scan revealed bilateral femoral
head ON without collapse. Coagulation studies revealed Factor V Leiden (FVL) heterozygosity, 4G/4G plasminogen
activator inhibitor (PAI) homozygosity, high anti-cardiolipin (ACLA) IgM antibodies, and endothelial nitric oxide (NO)
synthase (eNOS) T786C homozygosity (reduced conversion of L-arginine to NO, required for bone health). Apixaban
5 mg twice daily was substituted for warfarin; and L-arginine 9 g/day was started to increase NO. On Apixaban for
8 months, he became asymptomatic. Case 2: A 32-year-old hypogonadal Caucasian male had 10 years of
unexplained tooth loss, progressing to primary jaw ON with cavitation 8 months after starting TT gel 50 mg/day.
Coagulation studies revealed FVL heterozygosity, PAI 4G/4G homozygosity, and the lupus anticoagulant. TT was
discontinued. Jaw pain was sharply reduced within 2 months.
Conclusions: Idiopathic ON, often caused by thrombophilia-hypofibrinolysis, is worsened by TT, and its progression
may be slowed or stopped by discontinuation of TT and, thereafter, anticoagulation. Recognition of thrombophilia-
hypofibrinolysis before joint collapse facilitates anticoagulation which may stop ON, preserving joints.
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Osteonecrosis (ON) is often secondary to high-dose,
long-term steroids or alcoholism, with primary (idio-
pathic) ON defined when known secondary etiologies
are ruled-out [1]. The development of primary ON ap-
pears to follow a sequence of events initiated by familial
or acquired thrombophilia [2–4], venous occlusion caus-
ing osseous venous outflow obstruction, leading to in-
creased intraosseous venous pressure, reduced arterial
flow, ischemia, bone infarction and eventual joint col-
lapse [3–7]. Venous occlusion is the initiating event in* Correspondence: kevinspencerlee@gmail.com
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vent steroid induced ON [9]. Heritable or acquired
thrombophilia-hypofibrinolysis alone, or augmented by
testosterone therapy (TT) [9, 10] or clomiphene given to
raise testosterone (in men) [10] are thought to lead to
thrombotic venous occlusion and thence to osteonecro-
sis [3, 5–7]. In the current report, our specific aim was
to describe the association of familial thrombophilia
(Factor V Leiden heterozygosity), acquired thrombophi-
lia (lupus anticoagulant, high anticardiolipin [ACLA]
antibody IgM), and hypofibrinolysis (4G4G homozygos-
ity for the plasminogen activator inhibitor −1 mutation)
with hip and jaw ON, and the interaction of TT with fa-
milial thrombophilia in ON.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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Studies were carried out following a protocol approved
by the Institutional Review Board with signed informed
consent.
Cases with idiopathic osteonecrosis and Controls
To provide a frame of reference for the two cases in the
current report, thrombophilia-hypofibrinolysis measures
in 240 cases with idiopathic osteonecrosis sequentially
referred to our center for coagulation studies are pro-
vided, along with comparisons to 110 previously re-
ported healthy, normal controls [11] (48 men, 62
women). Controls were selected from healthy hospital
employees without osteonecrosis and without chronic
disease states.
Measures of thrombophilia and hypofibrinolysis
PCR measures of the Factor V Leiden, Prothrombin,
methylenetetrahydrofolate reductase (MTHFR), and
plasminogen activator inhibitor (PAI-1 gene) mutations
were done along with serologic measures of Lp (a),
homocysteine, factors VIII and XI, antigenic proteins C,
total S, free S, and antithrombin III, lupus anticoagulant,
and anticardiolipin antibodies (ACLA) IgG and IgM,
using previously reported methods [11, 12]. Serologic
tests were done before anticoagulation. Plasminogen ac-
tivator inhibitor-1 activity was not measured.
Statistical methods
The data were processed by SAS 9.4. Comparison of
measures of thrombophilia-hypofibrinolysis between
cases and controls was done by Chi-Square analysis, ex-
cepting those comparisons where the expected cell size




A 62-year-old Caucasian male had a past history of deep
venous thrombosis (DVT) in the right lower extremity
(1995, after cervical laminectomy), and superficial ven-
ous thrombosis of the right greater saphenous vein
(2003, after ablation procedure). He was receiving war-
farin for 1 year for paroxysmal atrial fibrillation (AF)
(status-post ablation and failed cardioversion). He was
evaluated for abdominal-flank-hip pain progressing over
a 2-year period. An abdominal CT scan revealed previ-
ously undiagnosed ON of both femoral heads without
collapse (Ficat [13] stage I). In absence of alcoholism,
high-dose long-term corticosteroid therapy, or any other
causes of secondary ON [6], the ON was thought to be
primary-idiopathic. Coagulation studies revealed throm-
bophilic Factor V Leiden (FVL) heterozygosity, hypofi-
brinolytic 4G/4G homozygosity for the PAI-1 gene,thrombophilic elevated ACLA IgM (24 MPL, mid posi-
tive 20–80 MPL) and eNOS T786C homozygosity asso-
ciated with reduced conversion of L-arginine to nitric
oxide (NO), required for normal bone health [14]. The
initial high ACLA IgM remained high on repeated test-
ing. There were no other features of the antiphospholi-
pid syndrome. Family screening revealed that both
daughters were heterozygous for the FVL mutation, and
one was homozygous for the PAI-1 4G/4G mutation. Be-
cause of difficulty maintaining an INR target of 2.5,
Apixaban 5 mg twice daily was substituted for warfarin.
L-arginine, 9 g/day, was given to increase NO produc-
tion [15]. After 8 months on Apixaban, he was asymp-
tomatic, but repeat imaging of the hips has not been
done. We speculated that the warfarin, given for 1 year
because of AF, may have concurrently stabilized his Ficat
stage I ON.
Case 2
A 32-year-old hypogonadal Caucasian male had a 10-
year history of unexplained progressive tooth erosion
and tooth loss. Tooth loss accelerated 8-months after
starting clomiphene (50 mg/day) to raise serum total
and free testosterone, and a CT scan revealed cavitating
ON of both jaws. The patient was referred to our center
by his dental surgeon for evaluation. There were no etio-
logic factors for secondary ON. There was no evidence
for excessive stomach acid or trauma (including teeth-
grinding) related to tooth erosion, and no alcohol abuse,
high-dose/long-term corticosteroids, or other secondary
causes of ON. He had never received bisphosphonates,
associated with jaw ON [16]. Coagulation studies re-
vealed heterozygosity for the FVL mutation, homozygos-
ity for the PAI-1 4G/4G mutation, and the lupus
anticoagulant was positive, and remained positive on re-
peat testing.
TT was discontinued, with a sharp reduction in jaw
pain within 2 months.
To provide a frame of reference to the two patients of
the current report, Table 1 [17] displays comparisons of
coagulation measures in 240 patients with primary ON
versus those in 110 healthy normal controls. Over a
period of 24 years beginning in 1992, we assessed 372
patients being referred for a new radiologic diagnosis of
ON of either the hip or knee [17, 18] of whom 240 had
primary idiopathic ON (not secondary to high dose-long
term corticosteroids, alcoholism, sickle cell disease, dis-
location, etc.). The 240 patients were compared against
healthy normal controls (n = 110), except in the com-
parison of eNOS [14] mutations for which only 72 his-
torical controls were evaluated. Due to diagnostic lab
testing limitations, not every control or patient was able
to be evaluated for every form of thrombophilia or hypo-
fibrinolysis. These results allowed us to estimate the
Table 1 Coagulation abnormalities in 240 patients with primary osteonecrosis, compared with 110 healthy normal controls
Coagulation measures Abnormal range Primary ON (n = 240) Normal controls (n = 110) Case vs control p a
Factor V Leiden TC, TT 21/235 (9%) 2/109 (2%) .014
Prothrombin gene TC, TT 9/228 (4%) 3/110 (3%) .76 (F)
MTHFR TT 46/226 (20%) 32/109 (29%) .068
PAI-1 gene 4G4G 66/225 (29%) 26/104 (25%) .42
Homocysteine Dated cut pointb 32/212 (15%) 5/107 (5%) .0061
ACLA IgG Dated cut pointc 11/210 (5%) 6/109 (6%) .92
ACLA IgM Dated cut pointd 27/209 (13%) 2/109 (2%) .0011
Lupus anticoagulant positive 2/203 (1%) 2/110 (2%) .61 (F)
Lp(a) ≥35 mg/dl 61/205 (30%) 21/107 (20%) .054
Factor VIII >150% 47/175 (27%) 7/103 (7%) <.0001
Factor XI >150% 15/169 (9%) 3/101 (3%) .060
Protein C <73% 10/204 (5%) 6/96 (6%) .63
Protein S <63% 1/206 (0.5%) 4/96 (4%) .037 (F)
Free S <66% 8/186 (4%) 2/96 (2%) .50 (F)
Antithrombin III <80 8/203 (4%) 2/96 (2%) .51 (F)
Compare with 72 controls
eNOS TC, TT 90/138 (65%) 28/72 (29%) .0003
acomparisons made by Chi-square test, unless there were cells which had expected counts <5 in 2 × 2 table where Fisher’s exact test (F) was used
bdated cut point for Homocysteine high: ≥15 (11/15/08-12/2/14); ≥10.4 (after 12/3/14)
c dated cut point for IgG high: ≥23 GPL (before 10/31/12); ≥15 (after 11/1/12)
d dated cut point for IgM high: ≥10 MPL (before 4/30/12); ≥13 (after 5/1/12)
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healthy controls without ON, and amongst patients with
primary ON, Table 1.
The two patients of our current report were heterozy-
gous for the FVL mutation, one had elevated ACLA, and
one was homozygous for the eNOS T786C mutation
[14]. Our 240 patients with primary ON differed from
normal controls by having FVL heterozygosity (like the
2 patients in the current report), high homocysteine,
high ACLA IgM, high Factor VIII, and hetero-
homozygosity for the eNOS T786C mutation, Table 1.
Discussion
Arthralgia of the hips [19] and knees [20] is a very com-
mon complaint in the outpatient setting, often requiring
diagnostic imaging studies [21–23]. Primary ON [6] is
not a common cause of arthralgia [24], and the diagnosis
and therapy of ON remains poorly understood by many
clinicians. While the prevalence of early-stage (pre-joint
collapse) primary ON appears to be relatively low [25], it
is important to diagnose, because, as we have shown,
treatment with long-term anticoagulation in patients
with familial or acquired thrombophilia-hypofibrinolysis
and with primary ON (Ficat [13] stage I-II, pre-joint col-
lapse) often results in complete symptomatic relief and
long-term joint preservation of both knees [7] and hips
[26], and may ameliorate osteonecrosis of the jaw [27].
The major clinical barrier to reaching this therapeuticbenefit is the lack of awareness of the association be-
tween thrombophilia- hypofibrinolysis with primary ON
[1, 3, 14, 28–31] which we are addressing in the current
report.
There appear to be etiologic associations between fac-
tor V Leiden heterozygosity [3, 28, 32], hyperhomocys-
teinemia [33], high ACLA IgM [34], high Factor VIII
[35], hetero-homozygosity for the T786C eNOS muta-
tion [14] and primary ON. ON, particularly multifocal,
occurs in patients with the antiphospholipid antibody
syndrome [36]. Exogenous testosterone therapy (TT) in
patients with familial or acquired thrombophilia-
hypofibrinolysis promotes development of ON [32, 37]
of the femoral head [32] and jaw [10].
In patients with early stage primary-idiopathic ON, be-
fore segmental collapse of hips or knees has occurred
(Ficat [13] stage I or II), with a heritable thrombophilia
or hypofibrinolysis, anticoagulation therapy of at least
1 year has been shown to arrest progression of ON and
lead to clinically significant pain relief [7, 26, 38, 39]. We
have previously [26] reported that long term anticoagu-
lation (4 to 16 years) stops progression of idiopathic hip
ON associated with familial thrombophilia (5 patients
with Factor V Leiden Heterozygotes and 1 patient with
resistance to activated protein C). On 4–16 years antic-
oagulation, 9 hips in these 6 patients, 8 originally Ficat
II, 1 Ficat 1 remained unchanged [26] in contrast to un-
treated ON Ficat stage II where 50–80% of hips progress
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[40, 41]. Left untreated, ON of the hip inevitably
leads to irreversible segmental or total joint collapse
[41] (i.e., Ficat III- IV) requiring joint replacement,
typically within 2 years of initial diagnosis [40–45].
There were no clinically significant bleeding episodes
[26]. Long term anticoagulation initiated in Ficat I II
idiopathic hip in patients heterozygous for the Factor V
Leiden mutation may change the natural history of the
disease [26].
Long term anticoagulation is also effective in thrombo-
philic patients with early (pre-collapse) primary ON of
the knee [7]. In 6 patients with knee osteonecrosis, all 6
with thrombophilia, 4 with concurrent hypofibrinolysis,
we determined prospectively whether anticoagulation
with Enoxaparin could prevent collapse, progression to
osteoarthritis, ameliorate pain, and restore function [7].
The 6 patients were treated with Enoxaparin (40–
60 mg/day for ≥ 3 months) as mandated by an FDA-
approved protocol. In post-Enoxaparin prospective
follow-up, patients were reassessed clinically every 4–6
months and X-rayed every year. The 6 patients had
follow-up for 15.1, 7.5, 3.9, 2.25, 2, and 1 years [7]. None
progressed to joint collapse or severe osteoarthritis; 4
became and remained asymptomatic at 2, 3.9, 7.5, and
15.1 year follow-up [7]. Thrombophilic-hypofibrinoytic
patients with knee ON treated with Enoxaparin have
had no collapse or progression to severe osteoarthritis;
and most have had resolution of pain and restoration of
full function [7].
In the jaw, when left untreated, ON leads to pro-
gressive tooth loss with failure to heal, jaw bone cavi-
tation, and chronic pain syndromes [10, 16].
Paralleling the patient in our current report, we have
previously reported a very similar case of primary ON
of the jaw in a 55 year old Caucasian man [10]. He
also had FVL heterozygosity, and rapid progression of
disease 6 months after starting TT gel 50 mg/day,
with development of high serum T (963 ng/dl, labora-
tory upper limit [46] 800 ng/dl) and high estradiol
(50 pg/ml, laboratory UNL 42.6 pg/ml). As in our
current patient, the development of jaw ON appeared
soon (6 months) after initiation of TT therapy [10],
which then interacted with the patient’s familial and
acquired thrombophilia and familial hypofibrinolysis,
promoting and worsening the jaw ON [18, 32]. We
have previously reported in a pilot study, that war-
farin therapy in patients with both Factor V Leiden
heterozygosity and osteonecrosis of the jaw was ef-
fective in reducing jaw pain [27].
In patients with thrombophilia-hypofibrinolysis and
thrombotic events on TT, continuation of TT, even with
adequate concurrent anticoagulation, leads to repetitive
thrombotic events [47].When the thrombus-promoting TT therapy is stopped,
and anticoagulation started, we speculate that venous
outflow is restored, increased venous pressure in the
bone is reduced, facilitating increased arterial flow, redu-
cing osseous ischemia [7, 26]. This is accompanied, as in
our current case of jaw ON, by reduction of symptoms,
and, in longer term anticoagulation studies, by stopping
and reversing osteonecrosis [7, 26]. It is relevant that ex-
perimental models of ON have shown venous occlusion
to be the initiating event [8, 48], and that treatment with
enoxaparin in experimental animals has the potential to
prevent steroid-associated ON [48]. Giving TT to mice
hetero-and homozygous for the Factor V Leiden muta-
tion [49, 50] and also having experimental antiphospho-
lipid syndrome [50], and using animal models of venous
occlusion and ON [8, 48] would allow basic science
studies of the relationship of TT and thrombophilia to
ON [18].
Historically, in adults with primary ON of weight bear-
ing joints, the most common treatments include invasive
forms of secondary and tertiary prevention, including
core decompression [51] with or without stem cell infu-
sion [52], vascularized fibular graft [53], and ultimately
total joint replacement [54]. Hence, new diagnoses of
ON, initially made by the radiologist and confirmed by
the orthopedic or dental surgeon or clinician [55], rarely
undergo a rigorous workup for thrombophilia or hypofi-
brinolysis [5]. This represents a clinically important
missed-opportunity as many patients may be inad-
equately treated for their joint pain [56] while
thrombophilia-hypofibrinolysis, a treatable [7, 26] causa-
tive etiology of primary ON (Ficat Stages I-II), goes
unaddressed [5].Conclusion
Primary ON is often caused by underlying familial
and acquired thrombophilia and hypofibrinolysis, and
can be worsened by TT or testosterone-elevating
clomiphene. In patients with primary ON, it is im-
portant for diagnostic and therapeutic reasons to de-
termine whether thrombophilia-hypofibrinolysis are
present, and whether TT is being used. To stop pro-
gression of early primary ON at Ficat Stage I or II
before joint collapse in patients with thrombophilia-
hypofibrinolysis, discontinuing TT is essential and
may slow or stop progression of the ON. Initiating
anticoagulation may stop progression of ON in
thrombophilic patients without joint collapse and
without progression to jaw cavitation, thus, avoiding
the usual natural history of untreated ON, which is
total joint replacement within 2 years of initial diag-
nosis, and in the jaw, chronic pain syndrome with
jaw cavitation and recurrent supra-infection.
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